MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 12-13-2025
Autolus Therapeutics plc Operating Cash Flow 2011-2025 | AUTL
Annual Operating Cash Flow Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -206 M | -146 M | -112 M | -118 M | -118 M | -101 M | -19.8 M | -16.4 M | -9.85 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -9.85 M | -206 M | -94.1 M |
Quarterly Operating Cash Flow Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -75.6 M | - | - | -40.5 M | - | - | -42.4 M | - | - | - | - | - | - | - | -37.3 M | - | - | - | -24 M | - | - | - | -26.5 M | -19.8 M | - | - | - | -8.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -8.8 M | -75.6 M | -34.4 M |
Operating Cash Flow of other stocks in the Biotechnology industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-481 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
-85.9 M | $ 4.79 | - | $ 795 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
-20.1 M | $ 3.04 | - | $ 235 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
-157 M | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-43.8 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-67.7 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
-1.19 M | $ 1.17 | - | $ 6.38 M |  China |
 |
Ampio Pharmaceuticals
AMPE
|
-8.56 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-93.9 M | - | - | $ 10.1 M | USA |
 |
Midatech Pharma plc
MTP
|
-6.01 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ascendis Pharma A/S
ASND
|
-418 M | $ 212.81 | 1.71 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
-23.8 M | $ 0.93 | - | $ 257 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-12.3 M | $ 3.1 | 0.16 % | $ 7.46 B |  Australia |
 |
BioVie
BIVI
|
-19 M | $ 1.27 | - | $ 1.88 M | USA |
 |
Biophytis SA
BPTS
|
-23.8 M | - | -13.47 % | $ 169 M |  France |
 |
Athersys
ATHX
|
-76.2 M | - | 3.77 % | $ 22.4 M | USA |
 |
Avenue Therapeutics
ATXI
|
-9.03 M | - | -52.27 % | $ 4.45 M | USA |
 |
ARCA biopharma
ABIO
|
-57.8 M | - | 1052.0 % | $ 415 M | USA |
 |
AVROBIO
AVRO
|
-63.2 M | - | 1083.1 % | $ 745 M | USA |
 |
Acasti Pharma
ACST
|
-14.9 M | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
-141 M | - | -15.15 % | $ 60.3 M | Britain |
 |
BioDelivery Sciences International
BDSI
|
41 M | - | -4.8 % | $ 255 M | USA |
 |
Albireo Pharma
ALBO
|
-108 M | - | -0.23 % | $ 916 M | USA |
 |
BioNTech SE
BNTX
|
890 M | $ 95.03 | - | $ 27.2 B | Germany |
 |
Amphastar Pharmaceuticals
AMPH
|
213 M | $ 26.81 | 1.36 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
-141 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Can-Fite BioPharma Ltd.
CANF
|
-7.64 M | $ 0.18 | 3.03 % | $ 392 M |  Israel |
 |
Anika Therapeutics
ANIK
|
-1.79 M | $ 9.48 | - | $ 139 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
-25.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
-47.5 M | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
-235 M | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-452 M | - | -6.81 % | $ 3.04 B | USA |
 |
Acer Therapeutics
ACER
|
-30.3 M | - | 2.71 % | $ 14 M | USA |
 |
Calithera Biosciences
CALA
|
-66.3 M | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
408 M | $ 591.15 | - | $ 44.8 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-34.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.94 M | $ 2.53 | -0.39 % | $ 15.9 M | USA |
 |
AstraZeneca PLC
AZN
|
5.96 B | $ 92.45 | - | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
-14 M | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
25.9 M | $ 12.37 | 2.06 % | $ 814 M | USA |
 |
Brickell Biotech
BBI
|
-4.34 M | - | -5.38 % | $ 6.06 M | USA |
 |
Burford Capital Limited
BUR
|
181 M | $ 9.0 | - | $ 1.48 B | Britain |
 |
Celldex Therapeutics
CLDX
|
-158 M | $ 26.83 | - | $ 1.73 M | USA |
 |
Cellectar Biosciences
CLRB
|
-32.4 M | $ 2.76 | - | $ 33.7 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-831 M | $ 10.81 | - | $ 699 M | USA |
 |
Biogen
BIIB
|
2.88 B | $ 176.33 | - | $ 25.7 B | USA |
|
Cerevel Therapeutics Holdings
CERE
|
-342 M | - | - | $ 7.29 B | USA |